预防性重组人血小板生成素在局限期小细胞肺癌同步放化疗中预防血小板减少的前瞻性多中心II期试验
该前瞻性多中心II期试验纳入56例接受依托泊苷联合铂类同步放化疗的局限期小细胞肺癌患者,放疗期间预防性皮下注射rhTPO。结果显示血小板最低值128.54±54.15×10^9/L,CTIT总发生率33.9%,无4-5级事件,无患者需血小板输注或放疗中断,支持进一步研究。
要点
- 预防性rhTPO使CTIT发生率33.9%,3级仅8.9%,无4-5级事件。
- 低基线血小板(<150×10^9/L)是CTIT独立危险因素(OR 4.26)。
- 无患者需血小板输注或放疗中断,仅1例需化疗减量。
核心结论
- 局限期小细胞肺癌同步放化疗期间预防性使用rhTPO可维持血小板计数,CTIT发生率低。
- 研究结果支持在高危CTIT患者中进一步研究rhTPO的预防策略。
研究设计与样本
- 前瞻性、多中心、II期临床试验,中国14家中心参与。
- 纳入56例接受依托泊苷联合顺铂或卡铂化疗同步放疗的局限期小细胞肺癌患者。
- 放疗期间皮下注射rhTPO 300 IU/kg/d,第1-5、8-12、15-19天给药;血小板≥300×10^9/L或较基线升高≥100×10^9/L时停药。
- 主要终点为血小板最低值和峰值。
主要发现
- rhTPO治疗期间血小板最低值为128.54±54.15×10^9/L,峰值为409.23±173.50×10^9/L。
- CTIT总发生率33.9%(19/56),其中3级8.9%(5/56),无4-5级事件。
- 78.9%(15/19)的患者在rhTPO治疗期间血小板恢复至≥100×10^9/L,中位恢复时间8天(95%CI 6-14)。
- 多因素logistic回归显示低基线血小板(<150×10^9/L)是CTIT独立危险因素(OR 4.26;95%CI 1.08-16.78;P=.038)。
- 无患者需血小板输注或放疗中断,仅1例需化疗减量;无严重不良事件,rhTPO相关不良反应少见且多为1级。
关键数值与推荐
- rhTPO给药方案:300 IU/kg/d皮下注射,放疗期间第1-5、8-12、15-19天。
- 停药标准:血小板计数≥300×10^9/L或较基线升高≥100×10^9/L。
- CTIT发生率33.9%(19/56),3级8.9%(5/56),无4-5级。
- 低基线血小板(<150×10^9/L)为CTIT独立危险因素(OR 4.26;95%CI 1.08-16.78;P=.038)。
临床怎么用
- 对局限期小细胞肺癌同步放化疗患者,可考虑预防性使用rhTPO以降低CTIT风险。
- 低基线血小板(<150×10^9/L)患者可能从预防性rhTPO中获益更多,需重点评估。
- 预防性rhTPO未增加严重不良事件,未导致放疗中断或血小板输注需求。
局限性
- 为单臂II期试验,无对照组,样本量56例,结论需随机对照研究验证。
- 随访时间短,长期生存和安全性数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Concurrent chemoradiation therapy is the standard therapy for limited-stage small cell lung cancer (LS-SCLC) but induces cancer therapy-induced thrombocytopenia (CTIT), which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin (rhTPO) in preventing CTIT in this patient population. METHODS AND MATERIALS: This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cisplatin or carboplatin chemotherapy with concurrent radiation therapy were given subcutaneous rhTPO (300 IU/kg/d) on days 1-5, 8-12, and 15-19 during radiation therapy. rhTPO treatment was stopped if platelet count reached ≥300 × 109/L or increased by ≥100 × 109/L from baseline. Primary endpoints were the nadir and peak platelet count. RESULTS: From March 8, 2024, to October 10, 2024, 56 LS-SCLC patients were enrolled. During the rhTPO treatment period, nadir platelet count (×109/L) was 128.54 ± 54.15, and peak platelet count reached 409.23 ± 173.50. Overall incidence of CTIT was 33.9% (19/56), including 8.9% (5/56) grade 3, and no grade 4-5 events. A total of 78.9% of patients (15/19) experienced platelet count recovery to ≥100 × 109/L during the rhTPO treatment period. Median time for platelet count recovery from <100 × 109/L to ≥100 × 109/L was 8 days (95% CI, 6-14). Multivariable logistic regression analysis revealed that low baseline platelet count (<150 × 109/L) was an independent risk factor for developing CTIT (odds ratio, 4.26; 95% CI, 1.08-16.78; P = .038). No patients required platelet transfusions or experienced radiation therapy interruptions, and only one patient required a reduction in the dose of chemotherapy throughout the entire study. Moreover, no serious adverse events were reported. rhTPO-related adverse reactions were infrequent and predominantly grade 1 (eg, transient platelet elevation). CONCLUSIONS: Prophylactic rhTPO during concurrent chemoradiation therapy for patients with LS-SCLC demonstrated a potential benefit in maintaining platelet counts with a low incidence of CTIT. These findings support further investigation of rhTPO as a preventive strategy for high risk CTIT patients.
引用
- Wang S, Zhao F, Wang J, et al. Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41831791. doi:10.1016/j.ijrobp.2026.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。